KLP Kapitalforvaltning AS Makes New Investment in Glaukos Co. (NYSE:GKOS)

KLP Kapitalforvaltning AS acquired a new position in Glaukos Co. (NYSE:GKOS - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 11,400 shares of the medical instruments supplier's stock, valued at approximately $1,709,000.

Other institutional investors have also recently bought and sold shares of the company. IFP Advisors Inc acquired a new stake in shares of Glaukos in the fourth quarter valued at approximately $43,000. Asset Planning Inc acquired a new stake in Glaukos during the fourth quarter worth approximately $90,000. Picton Mahoney Asset Management bought a new position in Glaukos during the 4th quarter worth $125,000. SBI Securities Co. Ltd. acquired a new position in Glaukos in the 4th quarter valued at $153,000. Finally, Smartleaf Asset Management LLC lifted its position in shares of Glaukos by 275.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,100 shares of the medical instruments supplier's stock valued at $164,000 after acquiring an additional 807 shares during the period. Institutional investors own 99.04% of the company's stock.

Insider Activity

In other Glaukos news, insider Tomas Navratil sold 3,416 shares of the stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $147.14, for a total transaction of $502,630.24. Following the completion of the sale, the insider now owns 72,437 shares of the company's stock, valued at approximately $10,658,380.18. This represents a 4.50 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Alex R. Thurman sold 1,520 shares of the firm's stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $106.84, for a total transaction of $162,396.80. Following the transaction, the chief financial officer now owns 53,431 shares of the company's stock, valued at approximately $5,708,568.04. The trade was a 2.77 % decrease in their position. The disclosure for this sale can be found here. Insiders own 6.40% of the company's stock.

Remove Ads

Glaukos Trading Up 3.1 %

Glaukos stock traded up $2.98 during trading hours on Wednesday, hitting $100.07. The stock had a trading volume of 810,071 shares, compared to its average volume of 607,015. The business's 50 day simple moving average is $126.91 and its 200-day simple moving average is $135.14. Glaukos Co. has a one year low of $89.94 and a one year high of $163.71. The stock has a market cap of $5.66 billion, a price-to-earnings ratio of -34.87 and a beta of 0.99. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19.

Glaukos (NYSE:GKOS - Get Free Report) last issued its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.02). Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The business had revenue of $105.50 million during the quarter, compared to the consensus estimate of $100.72 million. On average, equities analysts predict that Glaukos Co. will post -1.08 EPS for the current fiscal year.

Analyst Ratings Changes

GKOS has been the topic of a number of recent analyst reports. Stifel Nicolaus raised their price target on Glaukos from $153.00 to $175.00 and gave the stock a "buy" rating in a research report on Tuesday, December 31st. Citigroup upgraded shares of Glaukos from a "neutral" rating to a "buy" rating and boosted their target price for the company from $132.00 to $162.00 in a research report on Wednesday, December 11th. Mizuho upgraded shares of Glaukos from a "neutral" rating to an "outperform" rating and increased their price target for the stock from $140.00 to $200.00 in a research report on Wednesday, February 19th. Wells Fargo & Company lifted their price objective on shares of Glaukos from $153.00 to $160.00 and gave the company an "overweight" rating in a research note on Friday, February 21st. Finally, Piper Sandler restated an "overweight" rating and set a $180.00 target price (up from $140.00) on shares of Glaukos in a research note on Monday, January 27th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Glaukos has an average rating of "Moderate Buy" and an average target price of $163.25.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.